TherapeuticsMD, Inc. 8-K

Exhibit 99.1 




TherapeuticsMD Announces First Quarter 2019 Financial Results


-BIJUVA™ Commercial Launch in April 2019-

-Completed $300 Million Non-Dilutive Term Loan Financing Facility in April 2019-

-IMVEXXY® Continues Strong Positive Trends for Prescriptions and Patient Refills-

-Conference Call Scheduled for 4:30 p.m. ET Today-



BOCA RATON, Fla. May 6, 2019 – TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced its commercial and corporate update for the first quarter ended March 31, 2019.


“We are pleased with our recent progress on achieving several business objectives, which include the on-time launch of BIJUVA, the expansion of our sales force to 200 sales representatives who are now selling BIJUVA and IMVEXXY, the continued strong prescriptions and refills for IMVEXXY, and the significant strengthening of the company’s financial position with the completion of our $300 million non-dilutive term loan facility, which also increases our flexibility to support the launches of BIJUVA and ANNOVERATM,” said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD.


IMVEXXY Continues Strong Prescriptions and Refills

IMVEXXY prescription growth continues as highlighted by a record month in April 2019 with approximately 31,200 prescriptions dispensed and paid for by patients. Approximately 75,000 prescriptions of IMVEXXY were dispensed and paid for by patients during the first quarter of 2019. This is an increase of approximately 58% in prescription volume for the first quarter of 2019 as compared to the fourth quarter of 2018. Strong refill rates continue to indicate that women are having a positive experience with IMVEXXY.


Through April 30, 2019, the company achieved unrestricted coverage for IMVEXXY with seven of the top ten commercial payers of VVA products. One of these plans, United Healthcare, began adjudication on March 1, 2019. The company also achieved unrestricted Medicare Part D coverage on United Healthcare and Kaiser.


Summary of First Quarter 2019 Financial Results

Net revenues for the first quarter of 2019 were approximately $3.9 million, compared with net revenues of approximately $3.8 million for the prior year’s quarter. Net revenues for IMVEXXY for the first quarter of 2019 were approximately $2.0 million and were greatly affected by the company’s patient savings program introduced to launch IMVEXXY, which allows eligible patients to access the product at a reasonable cost of no more than $35 per prescription regardless of insurance coverage. The company expects revenues related to IMVEXXY to improve as commercial payer coverage for IMVEXXY increases and insurance plans complete the process needed to adjudicate IMVEXXY prescriptions at pharmacies.





Net revenues from the company’s prescription prenatal vitamin business were approximately $1.9 million for the first quarter of 2019, compared with approximately $3.8 million for the first quarter of 2018. A portion of the lower revenue was created by a price increase in the first quarter of 2019, causing some customers to increase purchases of the company’s prescription prenatal vitamins in the fourth quarter of 2018.

R&D expenses for the first quarter of 2019 were approximately $6.3 million, compared with approximately $7.0 million for the prior year’s quarter. The decrease in first quarter 2019 R&D expenses was primarily a result of the completion of the REPLENISH trial for BIJUVA and the FDA approval of IMVEXXY and BIJUVA, partially offset by scale-up and manufacturing activities for BIJUVA before FDA approval, as well as increased pre-clinical work to support our product pipeline.


Sales, general and administrative (SG&A) expenses for the first quarter of 2019 increased to approximately $34.9 million, compared with approximately $20.8 million for the prior year’s quarter. The increase in first quarter 2019 sales and marketing expenses was primarily a result of increased expenses associated with sales and marketing efforts to support the launch and commercialization of IMVEXXY and BIJUVA, including costs related to sales force expansion, outsourced sales personnel and their related expenses, physician education and product samples, and other expenses related to product commercialization. The company expects sales and marketing expenses to continue to increase as it continues the launch of BIJUVA, prepares for the launch of ANNOVERA and continues to support its growing business and commercialization of its products.


Net loss for the first quarter of 2019 was approximately $39.5 million, or $0.16 per basic and diluted share, compared with approximately $24.4 million, or $0.11 per basic and diluted share, for the first quarter of 2018.


Balance Sheet

As of March 31, 2019, the company’s cash on hand totaled approximately $122.9 million, compared with approximately $161.6 million at December 31, 2018. Total outstanding debt, net of issuance costs, was approximately $73.5 million as of March 31, 2019.

In April 2019, the company entered into a financing agreement for a $300 million non-dilutive term loan facility with TPG Sixth Street Partners (TSSP). The initial tranche of $200 million was drawn on April 24, 2019, with additional tranches of $50 million available to the company upon the designation of ANNOVERA as a new category of contraception by the U.S. Food and Drug Administration on or prior to December 31, 2019 and another $50 million available to the company upon achieving $11 million in net revenues from IMVEXXY, ANNOVERA and BIJUVA for the fourth quarter of 2019. A portion of the proceeds from the initial tranche of the TSSP facility was used to repay all amounts outstanding under the company’s prior credit facility.

Conference Call and Webcast Details


TherapeuticsMD will host a conference call and audio webcast today at 4:30 p.m. ET to discuss these financial results and provide a business update.


Date:   Monday, May 6, 2019
Time:   4:30 p.m. ET
Telephone Access (US):   866-665-9531
Telephone Access (International):   724-987-6977
Access Code for All Callers:   5799911





A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the TherapeuticsMD website at Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least 30 days. In addition, a digital recording of the conference call will be available for replay beginning two hours after the call's completion and for at least 30 days, with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 5799911.

Please see the Full Prescribing Information, including indication and Boxed WARNING, for each TherapeuticsMD product as follows: 

  IMVEXXY (estradiol vaginal inserts) at

  BIJUVA (estradiol and progesterone capsules) at

ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) at

About TherapeuticsMD, Inc.


TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.


Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA, BIJUVA and its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website:

Investor Contact

Nichol Ochsner

Vice President, Investor Relations

561-961-1900, ext. 2088







     March 31, 2019       December 31, 2018
Current Assets:          
Cash  $122,883,852   $161,613,077 
Accounts receivable, net of allowance for doubtful accounts of $678,886 and $596,602, respectively   14,944,750    11,063,821 
Inventory   4,955,715    3,267,670 
Other current assets   9,846,899    10,834,693 
     Total current assets   152,631,216    186,779,261 
Fixed assets, net   668,607    472,683 
Other Assets:          
License rights   20,000,000    20,000,000 
Intangible assets, net   4,455,730    4,092,679 
Other assets   3,821,566    324,855 
Security deposit   314,446    314,446 
     Total other assets   28,591,742    24,731,980 
       Total assets  $181,891,565   $211,983,924 
Current Liabilities:          
Accounts payable  $25,365,243   $22,743,841 
Other current liabilities   19,607,439    18,334,948 
     Total current liabilities   44,972,682    41,078,789 
Long-Term Liabilities:          
Long-term debt   73,501,160    73,381,014 
Opreating lease liability   2,724,501    —   
       Total liabilities   121,198,343    114,459,803 
Commitments and Contingencies          
Stockholders' Equity:          
 Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding   —      —   
Common stock - par value $0.001; 350,000,000 shares authorized: 241,221,840 and 240,462,439 issued and outstanding, respectively   241,222    240,463 
Additional paid-in capital   619,234,655    616,559,938 
Accumulated deficit   (558,782,655)   (519,276,280)
     Total stockholders' equity   60,693,222    97,524,121 
       Total liabilities and stockholders' equity  $181,891,565   $211,983,924 









   Three Months Ended
   March 31, 2019  March 31, 2018
Revenues, net  $3,946,651   $3,773,392 
Cost of goods sold   762,827    633,623 
Gross profit   3,183,824    3,139,769 
Operating expenses:          
Sales, general, and administrative   34,864,082    20,757,237 
Research and development   6,317,882    7,039,297 
Depreciation and amortization   106,938    59,621 
     Total operating expenses   41,288,902    27,856,155 
Operating loss   (38,105,078)   (24,716,386)
Other (expense) income          
Miscellaneous income   688,721    314,557 
Interest expense   (2,090,018)   —   
     Total (expense) income   (1,401,297)   314,557 
Loss before income taxes   (39,506,375)   (24,401,829)
Provision for income taxes   —      —   
Net loss  $(39,506,375)  $(24,401,829)
Loss per share, basic and diluted:          
Net loss per share, basic and diluted  $(0.16)  $(0.11)
 Weighted average number of common shares outstanding, basic and diluted   241,006,032    216,525,316 









   Three Months Ended
   March 31, 2019  March 31, 2018
 Net loss  $(39,506,375)  $(24,401,829)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation of fixed assets   66,494    38,424 
Amortization of intangible assets   40,444    21,197 
Non-cash operating lease expense   219,765    —   
Provision for doubtful accounts   82,284    22,955 
Share-based compensation   2,586,948    1,751,358 
Amortization of deferred financing costs   120,146    —   
Changes in operating assets and liabilities:          
Accounts receivable   (3,963,214)   (790,885)
Inventory   (1,688,045)   (135,514)
Other current assets   987,794    1,506,152 
Accounts payable   2,621,402    2,186,224 
Accrued expenses and other liabilities   268,939    152,223 
Net cash used in operating activities   (38,163,418)   (19,649,695)
 Patent costs   (403,496)   (142,136)
 Purchase of fixed assets   (262,418)   (26,908)
 Payment of security deposit   —      (11,486)
Net cash used in investing activities   (665,914)   (180,530)
Proceeds from exercise of options   100,107    44,057 
Net cash provided by financing activities   100,107    44,057 
Decrease in cash   (38,729,225)   (19,786,168)
Cash, beginning of period   161,613,077    127,135,628 
Cash, end of period  $122,883,852   $107,349,460 
Supplemental disclosure of cash flow information          
Interest paid   1,913,956    —   



The following information was filed by Therapeuticsmd, Inc. (TXMD) on Monday, May 6, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Therapeuticsmd, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Therapeuticsmd, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019) Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019) Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account